Close Menu

NEW YORK (360Dx) – While Congress appears unlikely to pass federal surprise billing legislation by the end of the year, the issue may become a focus for legislators, both on the federal as well as state level, in 2020.

Although laboratory services have not been at the forefront of the surprise billing discussion, they could see significant impacts from legislation, suggested Erin Duffy, a healthcare policy analyst at the University of Southern California's Leonard D. Schaeffer Center for Health Policy & Economics.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.